Capital International Investors Raises Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Capital International Investors boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,727,954 shares of the company’s stock after purchasing an additional 18,966 shares during the period. Capital International Investors owned approximately 0.24% of Teva Pharmaceutical Industries worth $55,105,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Menora Mivtachim Holdings LTD. boosted its stake in shares of Teva Pharmaceutical Industries by 31.9% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares during the last quarter. Soundwatch Capital LLC purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at $143,533,000. Maverick Capital Ltd. increased its position in Teva Pharmaceutical Industries by 14,351.6% during the second quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock valued at $73,370,000 after acquiring an additional 4,347,398 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Teva Pharmaceutical Industries by 13.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after purchasing an additional 3,896,790 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the subject of a number of recent research reports. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Jefferies Financial Group boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $30.46 on Thursday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock has a 50-day simple moving average of $33.00 and a two-hundred day simple moving average of $26.53. The firm has a market capitalization of $35.02 billion, a PE ratio of 25.38, a P/E/G ratio of 10.55 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter last year, the company earned $0.71 earnings per share. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 9,533 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $301,910.11. Following the completion of the sale, the insider directly owned 107,711 shares of the company’s stock, valued at $3,411,207.37. This represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the sale, the insider owned 10,914 shares in the company, valued at $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 948,499 shares of company stock worth $30,897,071 in the last 90 days. Insiders own 0.49% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.